BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ong S, Kim SE, Kim JH, Yi NH, Kim TY, Jung K, Park MI, Jung HY. Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial. Helicobacter. 2019;24:e12654. [PMID: 31411793 DOI: 10.1111/hel.12654] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Park CG, Kim S, Jeon HS, Han S. Validation of loop-mediated isothermal amplification to detect Helicobacter pylori and 23S rRNA mutations: A prospective, observational clinical cohort study. J Clin Lab Anal 2021;35:e23563. [PMID: 32893424 DOI: 10.1002/jcla.23563] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
3 Lee YD, Kim SE, Park SJ, Park MI, Moon W, Kim JH, Jung K, Song J. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection. Korean J Gastroenterol 2020;76:142-9. [PMID: 32969362 DOI: 10.4166/kjg.2020.76.3.142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lee JW, Kim SJ, Choi CW, Kim HJ, Kang DH, Kim HW, Park SB, Nam HS, Ryu DG. Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation. Medicine (Baltimore) 2021;100:e26133. [PMID: 34032763 DOI: 10.1097/MD.0000000000026133] [Reference Citation Analysis]
5 Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
6 Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34114673 DOI: 10.1111/jgh.15575] [Reference Citation Analysis]
7 Vazirzadeh J, Falahi J, Moghim S, Narimani T, Rafiei R, Karbasizadeh V. Molecular Assessment of Resistance to Clarithromycin in Helicobacter pylori Strains Isolated from Patients with Dyspepsia by Fluorescent In Situ Hybridization in the Center of Iran. Biomed Res Int 2020;2020:2304173. [PMID: 32309428 DOI: 10.1155/2020/2304173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Cho JH, Jin SY. Optimized diagnosis of Helicobacter pylori and tailored eradication therapy for preventing gastric cancer: a proposal for SHAKE strategy. Expert Rev Gastroenterol Hepatol 2020;14:553-64. [PMID: 32410515 DOI: 10.1080/17474124.2020.1770594] [Reference Citation Analysis]
9 Li SY, Li J, Dong XH, Teng GG, Zhang W, Cheng H, Gao W, Dai Y, Zhang XH, Wang WH. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 2021;26:e12804. [PMID: 33860967 DOI: 10.1111/hel.12804] [Reference Citation Analysis]
10 Saruuljavkhlan B, Yamaoka Y. Benefits of a Molecular-Based Method for the Detection of Clarithromycin-Resistant Helicobacter pylori. Gut Liver 2021;15:487-9. [PMID: 34261816 DOI: 10.5009/gnl210278] [Reference Citation Analysis]
11 Choi YI, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Seo JY, Park DK. Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients. World J Gastroenterol 2021; 27(31): 5247-5258 [PMID: 34497448 DOI: 10.3748/wjg.v27.i31.5247] [Reference Citation Analysis]
12 Liou JM, Lee YC, Wu MS. Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol 2020;35:1107-16. [PMID: 31984532 DOI: 10.1111/jgh.14992] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
13 Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021;160:1831-41. [PMID: 33524402 DOI: 10.1053/j.gastro.2020.11.059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]